The European AntibotABE Framework Program and Its Update: Development of Innovative Botulinum Antibodies
The goal of the AntiBotABE Program was the development of recombinant antibodies that neutralize botulinum neurotoxins (BoNT) A, B and E. These serotypes are lethal and responsible for most human botulinum cases. To improve therapeutic efficacy, the heavy and light chains (HC and LC) of the three Bo...
Main Authors: | Christine Rasetti-Escargueil, Arnaud Avril, Sebastian Miethe, Christelle Mazuet, Yagmur Derman, Katja Selby, Philippe Thullier, Thibaut Pelat, Remi Urbain, Alexandre Fontayne, Hannu Korkeala, Dorothea Sesardic, Michael Hust, Michel R. Popoff |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-10-01
|
Series: | Toxins |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6651/9/10/309 |
Similar Items
-
Neutralization of Botulinum Neurotoxin Type E by a Humanized Antibody
by: Yağmur Derman, et al.
Published: (2016-09-01) -
Human Botulism in France, 1875–2016
by: Christine Rasetti-Escargueil, et al.
Published: (2020-05-01) -
Antibodies against Anthrax Toxins: A Long Way from Benchlab to the Bedside
by: Arnaud Avril, et al.
Published: (2022-02-01) -
Recent Developments in Botulinum Neurotoxins Detection
by: Christine Rasetti-Escargueil, et al.
Published: (2022-05-01) -
A Four-Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotypes C and D
by: Consuelo Garcia-Rodriguez, et al.
Published: (2021-09-01)